Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes

被引：0
|
作者：
Lincoff, Abraham M. [1 ]
Brown-Frandsen, Kirstine [2 ]
Colhoun, Helen M. [3 ]
Deanfield, John [4 ]
Emerson, Scott S. [5 ]
Esbjerg, Sille [6 ]
Hardt-Lindberg, Soren [7 ]
Hovingh, G. Kees [8 ]
Kahn, Steven E. [9 ,10 ]
Kushner, Robert F. [11 ]
Lingvay, Ildiko [12 ]
Oral, Tugce Kalayci [8 ]
Michelsen, Marie M. [13 ]
Plutzky, Jorge [14 ]
Tornoee, Christoffer W. [15 ]
Ryan, Donna H. [16 ]
机构：
[1] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
[2] Novo Nordisk AS, Business Dev, Soborg, Denmark
[3] Univ Edinburgh, Inst Genet & Canc, Edinburgh, Midlothian, Scotland
[4] UCL, Dept Clin Sci, London, England
[5] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[6] Novo Nordisk AS, Dept Biostat, Soborg, Denmark
[7] Novo Nordisk AS, Project Management CKAD 5, Soborg, Denmark
[8] Novo Nordisk AS, Global Med Affairs, Soborg, Denmark
[9] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA
[10] Univ Washington, Seattle, WA 98195 USA
[11] Northwestern Univ, Dept Med & Med Educ, Chicago, IL 60611 USA
[12] UT SouthWestern Med Ctr, Dept Internal Med Endocrinol, Dallas, TX USA
[13] Novo Nordisk AS, Med & Sci, Soborg, Denmark
[14] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Med Div, Boston, MA 02115 USA
[15] Novo Nordisk AS, Obes Liver Dis & Devices, Soborg, Denmark
[16] Pennington Biomed Res Ctr, Clin Res, 6400 Perkins Rd, Baton Rouge, LA 70808 USA
来源：
CIRCULATION | 2023年 / 148卷 / 25期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
22962
引用
收藏
页码：E283 / E283
页数：1
相关论文
共 50 条
  • [31] Clinical outcomes of patients with gestational diabetes mellitus who do not have typical risk factors
    Nijjar, S. K.
    Hunt, K. F.
    Rogers, H.
    Smith, C.
    Gayle, C. M.
    Marsh, M. S.
    Amiel, S. A.
    Choudhary, P.
    DIABETOLOGIA, 2011, 54 : S479 - S480
  • [32] Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
    Deng, You
    Park, Andrew
    Zhu, Lin
    Xie, Wen
    Pan, Calvin Q.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
  • [33] Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
    Garg, Satish K.
    Kaur, Gurleen
    Haider, Zehra
    Rodriquez, Erika
    Beatson, Christie
    Snell-Bergeon, Janet
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (03) : 184 - 189
  • [34] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
    Deanfield, John
    Verma, Subodh
    Scirica, Benjamin M.
    Kahn, Steven E.
    Emerson, Scott S.
    Ryan, Donna
    Lingvay, Ildiko
    Colhoun, Helen M.
    Plutzky, Jorge
    Kosiborod, Mikhail N.
    Hovingh, G. Kees
    Hardt-Lindberg, Soren
    Frenkel, Ofir
    Weeke, Peter E.
    Rasmussen, Soren
    Goudev, Assen
    Lang, Chim C.
    Urina-Triana, Miguel
    Pietilae, Mikko
    Lincoff, A. Michael
    ELECT Trial Investigators, S. E. L. E. C. T. Trial Investigators
    LANCET, 2024, 404 (10454): : 773 - 786
  • [35] Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
    Lingvay, Ildiko
    Brown-Frandsen, Kirstine
    Colhoun, Helen M.
    Deanfield, John
    Emerson, Scott S.
    Esbjerg, Sille
    Hardt-Lindberg, Soren
    Hovingh, G. Kees
    Kahn, Steven E.
    Kushner, Robert F.
    Lincoff, A. Michael
    Marso, Steven P.
    Fries, Tea Monk
    Plutzky, Jorge
    Ryan, Donna H.
    OBESITY, 2023, 31 (01) : 111 - 122
  • [36] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes reply
    Husain, Mansoor
    Donsmark, Morten
    Bain, Stephen C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2076 - 2077
  • [37] Semaglutide Reduces Hospital Admissions in Patients with Obesity or Overweight and Established CVD
    Nicholls, Steven
    Ryan, Donna
    Deanfield, John
    Ferreira, Daniel
    Koroleva, Anna
    Lang, Chim
    Lincoff, A. Michael
    Lingvay, Ildiko
    Lubker, Christopher
    Madsen, Kathrine Pape
    Terns, Paula Perez
    Rasmussen, Soren
    Weeke, Peter
    Kahn, Steven
    OBESITY, 2024, 32 : 8 - 8
  • [38] Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews
    Hu, Xiaoye
    Wang, Yongsheng
    Yang, Kehu
    Li, Xiuxia
    ENDOCRINE, 2025,
  • [39] Cardiovascular Risk of Semaglutide in Patients With Type 2 Diabetes
    Marso
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (02) : 159 - 159
  • [40] Tirzepatide versus Semaglutide 2.4 mg for People with Obesity or Overweight and Type 2 Diabetes
    Hankosky, Emily
    Brumm, Julia Fraseur
    Malik, Raleigh
    Niemeyer, Anthony
    Wang, Fangyu
    Zhang, Xiaotian Michelle
    He, Xuanyao
    OBESITY, 2023, 31 : 83 - 84
12345